Skip to main content

Market Overview

Deutsche Bank Raises Achillion Price Target 183%

Share:

Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are trading higher after Deutsche Bank upgraded the stock from Hold to Buy and raised the price target from $6 to $17.

In the past, key concerns surrounded clinical and management execution. However, analyst Alethia Young writes that execution is improving and the appointment of a new CMO increases management prowess.

“Every 10% POS [probability of success for the nuke] is worth $5-6/sh. We currently assume Achillion peak sales of $3B (10% peak share) launching in ‘18 and a 5% lower price point vs. GILD,” says Young.

Deutsche Bank’s base case assumes a 40 percent chance of success.

Related Link: Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly

The report briefly touches on Achillion as a takeover target.

“We have always believed that having a nuke will be essential to a competitive long-term regimen in HCV. Currently only GILD, Merck, and ACHN have nukes that are in development or on market… [acquisition speculation] occurred after Idenix was acquired by Merck for ~$4B at similar stage as ACHN’s fall data readout.”

The $17 price target is based on a DCF with a 12 percent discount rate. Shares of Achillion were last up seven percent in pre-market trading to $9.90.

Latest Ratings for ACHN

DateFirmActionFromTo
Oct 2019SVB LeerinkDowngradesOutperformMarket Perform
May 2019BarclaysDowngradesEqual-WeightUnderweight
May 2018BarclaysUpgradesUnderweightEqual-Weight

View More Analyst Ratings for ACHN
View the Latest Analyst Ratings

 

Related Articles (ACHN)

View Comments and Join the Discussion!

Posted-In: Alethia Young Deutsche Bank Hepatits CAnalyst Color Upgrades Price Target Analyst Ratings

Latest Ratings

StockFirmActionPT
LBCredit SuisseMaintains36.0
TRGPCredit SuisseMaintains40.0
SNOWCredit SuisseMaintains275.0
DARCredit SuisseMaintains95.0
CLRMKM PartnersDowngrades26.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com